File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/JTO.0b013e31827628e1
- Scopus: eid_2-s2.0-84871960889
- PMID: 23196276
- WOS: WOS:000316204500024
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206
Title | Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206 |
---|---|
Authors | |
Keywords | Chemotherapy Radiotherapy Small-cell lung cancer Topoisomerase inhibitor |
Issue Date | 2013 |
Citation | Journal of Thoracic Oncology, 2013, v. 8 n. 1, p. 102-108 How to Cite? |
Abstract | INTRODUCTION: We sought to determine the efficacy of using both irinotecan-and etoposide-containing regimens sequentially for patients with untreated limited-stage small-cell lung cancer. METHODS: Patients with untreated, measurable, limited-stage small-cell lung cancer with performance status 0 to 2, and adequate organ function were eligible. Treatment consisted of induction with cisplatin 30 mg/m and irinotecan 65 mg/m intravenously on day 1 and 8, every 21 days for two cycles. Beginning day 43, daily chest irradiation to 70 Gy was administered concurrently with carboplatin area under curve 5 on day 1, and etoposide 100 mg/m on days 1 to 3, every 21 days for three cycles. The primary objective was to differentiate between 45% and 60% 2-year survival. RESULTS: Two induction cycles were delivered to 72 of 75 eligible patients (96%) and all planned treatment was delivered to 59 patients (79%). Cisplatin and irinotecan induction chemotherapy resulted in complete responses in 7% and partial responses in 64% (response rate 71%, 95% confidence interval [CI], 59%-81%). The best response to all therapy included 88% complete or partial responses (95% CI, 78%-94%). With median follow-up of 57 months, the median progression-free survival and overall survival are 12.6 (95% CI, 9.4-14.7) and 18.1 months (15.8-22.9), respectively. The 1-and 2-year survival was 69% and 31%, respectively. Frequent (>20%) grade 3 and 4 toxicities were neutropenia in 84%, hemoglobin in 36%, platelets in 51%, esophagitis in 22%, and dehydration in 24%. There were no fatal toxicities. CONCLUSIONS: This treatment regimen of irinotecan-cisplatin induction chemotherapy followed by 70 Gy concurrent radiation and etoposide-carboplatin had tolerable toxicity but did not meet the preplanned 2-year survival target for further development. Copyright © 2012 by the International Association for the Study of Lung Cancer. |
Persistent Identifier | http://hdl.handle.net/10722/194487 |
ISSN | 2023 Impact Factor: 21.0 2023 SCImago Journal Rankings: 7.879 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kelley, MJ | - |
dc.contributor.author | Bogart, JA | - |
dc.contributor.author | Hodgson, LD | - |
dc.contributor.author | Ansari, RH | - |
dc.contributor.author | Atkins, JN | - |
dc.contributor.author | Pang, H | - |
dc.contributor.author | Green, MR | - |
dc.contributor.author | Vokes, EE | - |
dc.date.accessioned | 2014-01-30T03:32:39Z | - |
dc.date.available | 2014-01-30T03:32:39Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Journal of Thoracic Oncology, 2013, v. 8 n. 1, p. 102-108 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.uri | http://hdl.handle.net/10722/194487 | - |
dc.description.abstract | INTRODUCTION: We sought to determine the efficacy of using both irinotecan-and etoposide-containing regimens sequentially for patients with untreated limited-stage small-cell lung cancer. METHODS: Patients with untreated, measurable, limited-stage small-cell lung cancer with performance status 0 to 2, and adequate organ function were eligible. Treatment consisted of induction with cisplatin 30 mg/m and irinotecan 65 mg/m intravenously on day 1 and 8, every 21 days for two cycles. Beginning day 43, daily chest irradiation to 70 Gy was administered concurrently with carboplatin area under curve 5 on day 1, and etoposide 100 mg/m on days 1 to 3, every 21 days for three cycles. The primary objective was to differentiate between 45% and 60% 2-year survival. RESULTS: Two induction cycles were delivered to 72 of 75 eligible patients (96%) and all planned treatment was delivered to 59 patients (79%). Cisplatin and irinotecan induction chemotherapy resulted in complete responses in 7% and partial responses in 64% (response rate 71%, 95% confidence interval [CI], 59%-81%). The best response to all therapy included 88% complete or partial responses (95% CI, 78%-94%). With median follow-up of 57 months, the median progression-free survival and overall survival are 12.6 (95% CI, 9.4-14.7) and 18.1 months (15.8-22.9), respectively. The 1-and 2-year survival was 69% and 31%, respectively. Frequent (>20%) grade 3 and 4 toxicities were neutropenia in 84%, hemoglobin in 36%, platelets in 51%, esophagitis in 22%, and dehydration in 24%. There were no fatal toxicities. CONCLUSIONS: This treatment regimen of irinotecan-cisplatin induction chemotherapy followed by 70 Gy concurrent radiation and etoposide-carboplatin had tolerable toxicity but did not meet the preplanned 2-year survival target for further development. Copyright © 2012 by the International Association for the Study of Lung Cancer. | - |
dc.language | eng | - |
dc.relation.ispartof | Journal of Thoracic Oncology | - |
dc.subject | Chemotherapy | - |
dc.subject | Radiotherapy | - |
dc.subject | Small-cell lung cancer | - |
dc.subject | Topoisomerase inhibitor | - |
dc.title | Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206 | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1097/JTO.0b013e31827628e1 | - |
dc.identifier.pmid | 23196276 | - |
dc.identifier.scopus | eid_2-s2.0-84871960889 | - |
dc.identifier.volume | 8 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 102 | - |
dc.identifier.epage | 108 | - |
dc.identifier.isi | WOS:000316204500024 | - |
dc.identifier.issnl | 1556-0864 | - |